Dr. Kremyanskaya on the Design of the MANIFEST Trial in Myelofibrosis
Marina Kremyanskaya, MD, PhD, discusses her research surrounding design of the phase 1 of 2 MANIFEST trial in myelofibrosis. Kremyanskay says, Pelabresib is an investigational oral small molecule inhibitor of bromodomain 1/2 of BET proteins.